NextCure exits remaining Beltsville lab space early, pays $0.8 million fee
The company terminated its lease for about 29,864 square feet in Beltsville, Maryland effective September 1, 2026, ahead of the original term.
SEC filing
Latest
4 stories
Thursday, September 3
Thursday, August 13
NextCure's NC410-pembrolizumab trial ends after Phase 1b; Part 2 never launched
Thursday, August 6
NextCure reports Q2 2026 results, moves toward Avere Therapeutics merger
NextCure is preserving cash ahead of a planned merger with Avere Therapeutics that includes a roughly $320 million private financing, while winding down its own clinical programs.
SEC filing
Tuesday, July 14
NextCure and Avere Therapeutics agree to all-stock merger, $320 million private placement
Combined company plans to advance oral IL-23 antagonist AVR-001 and trade as Avere Therapeutics under ticker AVRX.
SEC filing